Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues.

IF 2.6 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Arrhythmia & Electrophysiology Review Pub Date : 2023-01-01 DOI:10.15420/aer.2023.04

Manyoo A Agarwal, Aadhavi Sridharan, Rhea C Pimentel, Steven M Markowitz, Lynda E Rosenfeld, Michael G Fradley, Eric H Yang

{"title":"Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues.","authors":"Manyoo A Agarwal, Aadhavi Sridharan, Rhea C Pimentel, Steven M Markowitz, Lynda E Rosenfeld, Michael G Fradley, Eric H Yang","doi":"10.15420/aer.2023.04","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular disease and cancer are the leading causes of morbidity and mortality in the US. Despite the significant progress made in cancer treatment leading to improved prognosis and survival, ventricular arrhythmias (VA) remain a known cardiovascular complication either exacerbated or induced by the direct and indirect effects of both traditional and novel cancer treatments. Although interruption of cancer treatment because of VA is rarely required, knowledge surrounding this issue is essential for optimising the overall care of patients with cancer. The mechanisms of cancer-therapeutic-induced VA are poorly understood. This review will discuss the ventricular conduction (QRS) and repolarisation abnormalities (QTc prolongation), and VAs associated with cancer therapies, as well as existing strategies for the identification, prevention and management of cancer-treatment-induced VAs.</p>","PeriodicalId":8412,"journal":{"name":"Arrhythmia & Electrophysiology Review","volume":"12 ","pages":"e16"},"PeriodicalIF":2.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/89/aer-12-e16.PMC10345968.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arrhythmia & Electrophysiology Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/aer.2023.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 2

Abstract

Cardiovascular disease and cancer are the leading causes of morbidity and mortality in the US. Despite the significant progress made in cancer treatment leading to improved prognosis and survival, ventricular arrhythmias (VA) remain a known cardiovascular complication either exacerbated or induced by the direct and indirect effects of both traditional and novel cancer treatments. Although interruption of cancer treatment because of VA is rarely required, knowledge surrounding this issue is essential for optimising the overall care of patients with cancer. The mechanisms of cancer-therapeutic-induced VA are poorly understood. This review will discuss the ventricular conduction (QRS) and repolarisation abnormalities (QTc prolongation), and VAs associated with cancer therapies, as well as existing strategies for the identification, prevention and management of cancer-treatment-induced VAs.

Abstract Image

查看原文本刊更多论文

癌症患者室性心律失常:机制、治疗策略和未来途径。

心血管疾病和癌症是美国发病率和死亡率的主要原因。尽管在癌症治疗方面取得了重大进展，导致预后和生存改善，室性心律失常(VA)仍然是一种已知的心血管并发症，传统和新型癌症治疗的直接或间接作用加剧或诱发了室性心律失常。虽然很少需要因VA而中断癌症治疗，但围绕这一问题的知识对于优化癌症患者的整体护理至关重要。癌症治疗诱导VA的机制尚不清楚。本文将讨论心室传导(QRS)和复极异常(QTc延长)，以及与癌症治疗相关的VAs，以及癌症治疗诱导的VAs的识别、预防和管理的现有策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arrhythmia & Electrophysiology Review CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

5.10

自引率

6.70%

发文量

审稿时长

7 weeks